Sep 12, 2022 / 03:40PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hey, guys. Thanks for joining us. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst here at Morgan Stanley. It's my pleasure to host Olink this morning, and we have Jon and Oskar representing the company. Before we kick things off, I just need to read an important disclosure. Please see the Morgan Stanley Research Disclosure website at morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your sales rep. So with that, Jon, maybe just to set the stage a little bit, can you just talk about what you view as the key accomplishments over the last 6 to 12 months for Olink? And what are some of the key opportunities in gold as you think about 2023?
Jon Heimer - Olink Holding AB(publ)-CEO&Director
Sure thing. And first of all, thanks for hosting us here, Tejas. Great to be here. Yes. No, if we look at our business from a broader perspective, I mean, super excited by the development we
Olink Holding AB (publ) at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers